Research & Development

Research & Development

Initial focus on psilocybin for depression based on evidence of efficacy. Proprietary formulations to enhance release profile of active drug and secure Intellectual Property

CandidateMoleculeDeliveryIndicationDevelopment StatusPartners
WP001Psilocybin (low dose)Rapid release CapsuleModerate DepressionEthics approval received for Phase IIB trial Macquarie University
WP002Psilocybin (high dose)Rapid release TabletTreatment-Resistent DepressionEthics approval received for Phase IIB trial Imperial College London Drug Science (UK) Swinburne University
WP002Psilocybin (high dose)Rapid release TabletAlcohol use disorderEthics approval received for Phase IIB trial University of Sydney
WP002Psilocybin (high dose)Rapid release TabletProlonged griefEthics submission for Phase II feasibility trial in progress QIMR-Berghofer
WP002Psilocybin (high dose)Rapid release tabletChronic musculoskeletal painEthics submission for Phase II trial in Q2 CY2023 Curtin University
WP003LSD (novel analogue)EnhancedAnxiety, Substance Abuse, PTSDDrug discovery – in-vitro data H1 CY2023 University of Western Australia

WP001 is a low-dose psilocybin drug candidate for treatment of moderate depression. It was formulated with Monash University’s Medicines Manufacturing Innovation Centre (MMIC, VIC), as a novel rapid-release capsule.

In collaboration with Macquarie University, NSW, a Phase IIB trial is progressing through ethics approval, with enrolment anticipated to commence in Q1 CY2023. The trial will enrol over 260 patients with moderate depression in a randomised, controlled study. The primary endpoint will be the Grid-Hamilton Depression Score, with secondary endpoints that include biomarkers, physiological and neurophysiological measures.

Patients interested in the Phase IIB trial of WP001 to treat moderate depression should contact info@wokeph.com


WP002 is a high-dose psilocybin drug candidate with concomitant psychotherapy, which has been formulated with MMIC, as a novel rapid-release tablet.

In collaboration with Swinburne University, VIC, a Phase IIB trial in patients with treatment-resistant depression is progressing through ethics approval, with enrolment anticipated at multiple sites in Australia in Q1/2 CY2023. This trial is also a collaboration with UK-based Drug Science, led by Professor Dave Nutt at Imperial College London. The Phase IIB trial will enrol approximately 160 patients with treatment-resistant depression in a randomised, controlled study. The primary endpoint will be the MADRS Depression Score, with secondary endpoints that include physiological and neurophysiological measures as well as health economic measures. 

In collaboration with QIMR Berghofer, QLD,  a feasibility Phase II trial to treat prolonged grief disorder is progressing through ethics approval, with enrolment anticipated in Q1 CY2023. The trial, named PARTING: Psilocybin-Assisted supportive psychoTherapy IN the treatment of prolonged Grief, will enrol approximately 15 patients with the intention of demonstrating intervention acceptability and proof-of-concept efficacy. The intervention will include three preparatory psychotherapy sessions, one WP002 psilocybin dosing session and six post-experience psychotherapy integration sessions.

In collaboration with the University of Sydney, NSW, the design of a Phase IIB trial to treat patients with alcohol use disorder is being finalised. Outcomes will be assessed monthly for three months using standard measures for alcohol research approved by the FDA including abstinence and no heavy drinking days. The trials will enrol approximately 60 patients.

In collaboration with Curtin University, WA, a Phase IIB trial to treat patients with chronic musculoskeletal pain is being designed. The trial will enrol approximately 50 patients.

Patients interested in the trials of WP002 to treat treatment-resistant depression, prolonged grief, alcohol use disorder or chronic musculoskeletal pain should contact info@wokeph.com


WP003 is working with researchers at the University of Western Australia to discover novel analogues of LSD  (lysergic acid diethylamide) for treatment of anxiety, substance abuse and other mental health disorders. Through novel chemistry, Woke Pharmaceuticals aims to enhance the efficacy and solve some of the challenges that have limited the therapeutic application of LSD.